Sawai to Launch Teribone Generic as Court Invalidates Patents; Asahi Kasei to Challenge Ruling

February 17, 2022
Sawai Pharmaceutical won approval for a generic version of Teribone (teriparatide) on February 15 after a court supported all its patent invalidation claims for the major osteoporosis drug. This sets the stage for the listing of its generic in June...read more